A Phase 2/3 interventional study of Verteporfin Photodynamic Therapy and Ranibizumab in Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis. Terminated at 12 sites in 12 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-04-21.
Sponsored by Novartis · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing verteporfin in Macular Degeneration — none open to participants now, none under way, none of them phase 3. Verteporfin · Macular Degeneration.
Among the 18 studies testing verteporfin in Macular Degeneration, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2007, is the only one in phase 2/3, and was the 8th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →None of the 18 studies testing verteporfin in Macular Degeneration is open now. The open studies under Macular Degeneration, anywhere →
Verteporfin: first FDA approval 2000 (VISUDYNE), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 5 · Phase 4 6
First in 2002; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 60 across the 17 interventional studies. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 18th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2007, is the only one in phase 2/3, and was the 8th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing verteporfin in Macular Degeneration, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Verteporfin (6 mg/m\^2) photodynamic therapy (PDT) and ranibizumab (0.5 mg). Patients received three consecutive monthly ranibizumab injections starting on Day 1, and then as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
Drug: Verteporfin Photodynamic Therapy · Drug: Ranibizumab
Patients received three consecutive monthly ranibizumab injections starting on Day 1 and then as needed from Month 3 based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
Drug: Ranibizumab · Drug: Placebo
After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of the infusion.
Also known as: Visudyne
Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
Also known as: Lucentis
As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Change From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12.
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.
Time frame: Baseline and Month 12
Percent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
The number of patients with a ranibizumab treatment-free interval, ie, no active ranibizumab treatments for at least 3 months duration (at least 2 consecutive monthly visits), anytime following the Month 2 ranibizumab treatment. Only active ranibizumab treatments were considered.
Time frame: Month 2 to Month 11
Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 12
The proportion of patients with leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).
Time frame: Month 12
Mean Change in Total Area of Leakage (Observed) of the Study Eye at Month 12
Fluorescein angiography (FA) was used to assess the mean change of leakage of the study eye at the Central Reading Center (CRC). A negative change from baseline indicates improvement, ie, less leakage.
Time frame: Baseline and Month 12
Mean Change in Central Retinal Thickness of the Study Eye at Month 12
Optical coherence tomography (OCT) was used to assess the mean change in retinal thickness of the study eye at the Central Reading Center (CRC). A negative change from baseline indicates improvement, ie, less thickness.
Time frame: Baseline and Month 12
| Milestone | Verteporfin + Ranibizumab | Ranibizumab |
|---|---|---|
| Started | 122 | 133 |
| Completed 12 month phase | 114 | 126 |
| Completed | 26 | 32 |
| Not completed | 96 | 101 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Administrative problems | 80 | 86 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Subject no longer requires study drug | 1 | 1 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.
| Letters | Verteporfin + Ranibizumab | Ranibizumab |
|---|---|---|
| Baseline | 54.6 ± 13.5 | 55.1 ± 12.3 |
| Month 12 | 57.1 ± 18.3 | 59.4 ± 18.8 |
| Change from Baseline | 2.5 ± 14.82 | 4.4 ± 15.92 |
The number of patients with a ranibizumab treatment-free interval, ie, no active ranibizumab treatments for at least 3 months duration (at least 2 consecutive monthly visits), anytime following the Month 2 ranibizumab treatment. Only active ranibizumab treatments were considered.
| Percentage of Participants | Verteporfin + Ranibizumab | Ranibizumab |
|---|---|---|
| Percent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit | 95.8 | 92.2 |
The proportion of patients with leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).
| Percentage of participants | Verteporfin + Ranibizumab | Ranibizumab |
|---|---|---|
| Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 12 | 28.9 | 25.2 |
Fluorescein angiography (FA) was used to assess the mean change of leakage of the study eye at the Central Reading Center (CRC). A negative change from baseline indicates improvement, ie, less leakage.
| mm^2 | Verteporfin + Ranibizumab | Ranibizumab |
|---|---|---|
| Baseline | 7.4 ± 4.63 | 8.1 ± 5.82 |
| Month 12 | 2.2 ± 4.88 | 2.0 ± 4.68 |
| Change from Baseline | -5.3 ± 5.32 | -6.1 ± 6.44 |
Optical coherence tomography (OCT) was used to assess the mean change in retinal thickness of the study eye at the Central Reading Center (CRC). A negative change from baseline indicates improvement, ie, less thickness.
| μm | Verteporfin + Ranibizumab | Ranibizumab |
|---|---|---|
| Baseline | 335.2 ± 94.7 | 339.8 ± 125.6 |
| Month 12 | 219.9 ± 61.1 | 232.0 ± 54.5 |
| Change from Baseline | -115.3 ± 98.7 | -107.7 ± 124.6 |
Collected over Includes cumulative data through 24 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Verteporfin + Ranibizumab | — | 25/122 (20.5%) | 64/122 (52.5%) |
| Ranibizumab | — | 28/133 (21.1%) | 63/133 (47.4%) |
| Event | Verteporfin + Ranibizumab | Ranibizumab |
|---|---|---|
| FALLInjury, poisoning and procedural complications | 4/122 | 2/133 |
| CEREBROVASCULAR ACCIDENTNervous system disorders | 1/122 | 4/133 |
| CARDIAC FAILURECardiac disorders | 2/122 | 0/133 |
| MYOCARDIAL INFARCTIONCardiac disorders | 2/122 | 0/133 |
| VISUAL ACUITY REDUCED (Study eye)Eye disorders | 2/122 | 1/133 |
| PERIPHERAL ARTERIAL OCCLUSIVE DISEASEVascular disorders | 2/122 | 0/133 |
| CATARACT (Study eye)Eye disorders | 0/122 | 2/133 |
| RENAL NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/122 | 2/133 |
| DIZZINESSNervous system disorders | 0/122 | 2/133 |
| ANGINA PECTORISCardiac disorders | 1/122 | 1/133 |
| Event | Verteporfin + Ranibizumab | Ranibizumab |
|---|---|---|
| HYPERTENSIONVascular disorders | 19/122 | 13/133 |
| NASOPHARYNGITISInfections and infestations | 18/122 | 15/133 |
| INTRAOCULAR PRESSURE INCREASED (Study eye)Investigations | 11/122 | 8/133 |
| EYE PAIN (Study eye)Eye disorders | 10/122 | 8/133 |
| CONJUNCTIVAL HAEMORRHAGE (Study eye)Eye disorders | 4/122 | 10/133 |
| OCULAR HYPERAEMIA (Study eye)Eye disorders | 7/122 | 10/133 |
| INFLUENZAInfections and infestations | 3/122 | 9/133 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 8/122 | 3/133 |
| MACULAR DEGENERATION (Fellow eye)Eye disorders | 4/122 | 8/133 |
| RETINAL HAEMORRHAGE (Study eye)Eye disorders | 7/122 | 5/133 |
| Age Continuous(years) | Verteporfin + Ranibizumab | Ranibizumab | Total |
|---|---|---|---|
| Mean | 76.8 ± 7.65 | 75.5 ± 7.44 | 76.1 ± 7.55 |
| Sex: Female, Male(Participants) | Verteporfin + Ranibizumab | Ranibizumab | Total |
|---|---|---|---|
| Female | 78 | 74 | 152 |
| Male | 44 | 59 | 103 |
The record gives a start of May 2007, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Verteporfin